Optimizing Treatment Strategies for HR+/HER2- Breast Cancer: ESR1 Mutations and Emerging Therapies : Episode 1
Opinion
Video
Prevalence and Testing Strategies for ESR1
Virginia Kaklamani, MD, DSc, and Heather McArthur, MD, explore the clinical significance of *ESR1* mutations in HR+/HER2- metastatic breast cancer patients, including their impact on disease prognosis, treatment outcomes, and the increasing prevalence of these mutations with each line of endocrine therapy, ultimately informing their therapeutic approach.
- What are the clinical implications of ESR1 mutations for disease prognosis and treatment outcomes in HR+/HER2- mBC patients?
- How does the increasing prevalence of ESR1 mutations with each line of endocrine therapy inform your treatment approach and decision-making process?
Related Videos
Related Content
